<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03839121</url>
  </required_header>
  <id_info>
    <org_study_id>CR024</org_study_id>
    <nct_id>NCT03839121</nct_id>
  </id_info>
  <brief_title>Safety and Performance Aspects of CRT-DX System in Patients With Sinus Rhythm</brief_title>
  <acronym>BIO|REDUCE</acronym>
  <official_title>BIO|REDUCE: Cardiac REsynchronization Therapy With Two Ventricular Leads and Right Atrial Floating Diagnostic Dipole Installed in the Right ventricUlar Lead in Patients With CRT-D indiCation and no Sinus nodE Dysfunction</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Biotronik SE &amp; Co. KG</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Biotronik SE &amp; Co. KG</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The conventional CRT-D system consists of 3 leads in patients with Heart Failure (HF). A part&#xD;
      of HF patients have non-impaired sinus node function and will not be stimulated in the right&#xD;
      atrium. The implantation of the right atrial lead, which is not mandatory in these patients,&#xD;
      harbors potential complication risks and prolongs implantation procedure. The new CRT-DX&#xD;
      system uses 2 leads only: a right ventricular lead extended with floating RA sending dipole&#xD;
      and a left ventricular lead. The aim of the BIO|REDUCE study is to assess the residual safety&#xD;
      and performance aspects of the CRT-DX system within 12 months follow-up in HF patients with&#xD;
      an indication for a CRT-D, sinus rhythm, and no need for an atrial lead implantation.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 1, 2019</start_date>
  <completion_date type="Anticipated">May 2023</completion_date>
  <primary_completion_date type="Anticipated">December 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Number of implantation of a right atrial lead after conclusion of the initial study device implantation</measure>
    <time_frame>through study completion, on average 12 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of post-operative system revisions requiring an invasive re-intervention</measure>
    <time_frame>through study completion, on average 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of lead complications requiring an invasive re-intervention</measure>
    <time_frame>through study completion, on average 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of device or pocket infections requiring an invasive re-intervention</measure>
    <time_frame>through study completion, on average 12 months</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>Documentation of patient characteristics and medication</measure>
    <time_frame>through study completion, on average 12 months</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Assessment of patients benefit from CRT</measure>
    <time_frame>Baseline, 3, 6 and 12 months</time_frame>
    <description>Documentation of NYHA class</description>
  </other_outcome>
  <other_outcome>
    <measure>Documentation of LVEF</measure>
    <time_frame>6 and 12 months (optional for PHD and 3 months)</time_frame>
    <description>Left ventricular ejection fraction [%]</description>
  </other_outcome>
  <other_outcome>
    <measure>Documentation of LVESV</measure>
    <time_frame>6 and 12 months (optional for PHD and 3 months)</time_frame>
    <description>Left ventricular end-systolic volume [ml]</description>
  </other_outcome>
  <other_outcome>
    <measure>Documentation of LVEDV</measure>
    <time_frame>6 and 12 months (optional for PHD and 3 months)</time_frame>
    <description>Left ventricular end-diastolic volume [ml]</description>
  </other_outcome>
  <other_outcome>
    <measure>Documentation of atrial sensing amplitude</measure>
    <time_frame>through study completion, on average 12 months</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Documentation of statistics of device pacing counters</measure>
    <time_frame>through study completion, on average 12 months</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Documentation of programming of a non-AV-sequential pacing mode (e.g. VVI) except if justified by atrial fibrillation</measure>
    <time_frame>through study completion, on average 12 months</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Documentation of implantation data</measure>
    <time_frame>through study completion, on average 12 months</time_frame>
    <description>e.g. implantation time, lead position</description>
  </other_outcome>
  <other_outcome>
    <measure>Number of serious adverse events</measure>
    <time_frame>through study completion, on average 12 months</time_frame>
    <description>Documentation of serious adverse events</description>
  </other_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">110</enrollment>
  <condition>Heart Failure</condition>
  <condition>Cardiac Resynchronization Therapy</condition>
  <arm_group>
    <arm_group_label>single arm: CRT-DX</arm_group_label>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Cardiac Resynchronization Therapy (CRT)</intervention_name>
    <description>Observation and documentation of CRT patients</description>
    <arm_group_label>single arm: CRT-DX</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with Cardiac Resynchronization Therapy Defibrillator (CRT-D) indication according&#xD;
        to the current guidelines, who are in sinus rhythm without history of atrial fibrillation&#xD;
        (AF) and do not require right atrial (RA) lead implantation at study enrolment.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patient is able to understand the nature of study and has provided written informed&#xD;
             consent.&#xD;
&#xD;
          -  Patient is willing and able to perform all follow up visits at the study site.&#xD;
&#xD;
          -  Patient is willing and able to use the CardioMessenger® and accepts the BIOTRONIK Home&#xD;
             Monitoring® concept.&#xD;
&#xD;
          -  CRT-D is indicated according to the current ESC guidelines.&#xD;
&#xD;
          -  De novo implantation with no pre-existing defibrillator or pacemaker system&#xD;
&#xD;
          -  Patient is in sinus rhythm without history of atrial fibrillation.&#xD;
&#xD;
          -  Patient has no atrioventricular (AV) block I or higher (PR interval more than 200 ms).&#xD;
&#xD;
          -  Patient has no evidence of impaired sinus node function.&#xD;
&#xD;
          -  Patient has no need for atrial stimulation, has a resting heart rate (HR) &gt; 40 b.p.m&#xD;
             and achieves a peak HR ≥100 b.p.m even under intended dosage of HR lowering medication&#xD;
             verified by an appropriate method as clinical routine examination within 3 months&#xD;
             prior to enrollment&#xD;
&#xD;
          -  NYHA class II or III&#xD;
&#xD;
          -  Patient receives guideline-based optimized medical therapy for HF including heart-rate&#xD;
             lowering medication at the time of enrollment&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patient is pregnant or breast feeding.&#xD;
&#xD;
          -  Patient is less than 18 years old.&#xD;
&#xD;
          -  Patient is participating in an interventional clinical investigation.&#xD;
&#xD;
          -  Life-expectancy is less than 1 year.&#xD;
&#xD;
          -  Patient has tachycardia-bradycardia syndrome&#xD;
&#xD;
          -  Any standard contraindication for CRT-D&#xD;
&#xD;
          -  Frequent premature ventricular contractions (PVC rate &gt; 5 %/h) examined within 3&#xD;
             months prior to enrollment by appropriate routine method (e.g. 24 h holter&#xD;
             electrocardiogram)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dietmar Bänsch, Prof.</last_name>
    <role>Principal Investigator</role>
    <affiliation>KMG Kliniken, Güstrow</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Christof Kolb, Prof.</last_name>
    <role>Principal Investigator</role>
    <affiliation>DHM, München</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Angelika Felk, Dr.</last_name>
    <phone>+49 (0) 151 16321781</phone>
    <email>bioreduce.study@biotronik.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Kepler University Clinic</name>
      <address>
        <city>Linz</city>
        <country>Austria</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Steinwender, Prof</last_name>
    </contact>
    <investigator>
      <last_name>Steinwender, Prof</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Fakultni Nemocnice Hradec Králové</name>
      <address>
        <city>Králová</city>
        <country>Czechia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Parizek, Dr</last_name>
    </contact>
    <investigator>
      <last_name>Parizek, Dr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Fakultni Nemocnice Olomouc</name>
      <address>
        <city>Olomouc</city>
        <country>Czechia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Doupal, Dr</last_name>
    </contact>
    <investigator>
      <last_name>Doupal, Dr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Zentralklinik Bad Berka</name>
      <address>
        <city>Bad Berka</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Charitè University Clinic, Campus Benjamin Franklin</name>
      <address>
        <city>Berlin-Steglitz</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Huemer, Dr</last_name>
    </contact>
    <investigator>
      <last_name>Huemer, Dr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Herzzentrum Dresden Univesity Clinic at Technical University Dresden</name>
      <address>
        <city>Dresden</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Städtisches Klinikum Dresden, Friedrichstadt</name>
      <address>
        <city>Dresden</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Schellong, Prof</last_name>
    </contact>
    <investigator>
      <last_name>Schellong, Prof.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Evangelical Hospital Düsseldorf</name>
      <address>
        <city>Düsseldorf</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>University Clinic Erlangen</name>
      <address>
        <city>Erlangen</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Arnold, Dr</last_name>
    </contact>
    <investigator>
      <last_name>Arnold, Dr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Clinic Würzburg</name>
      <address>
        <city>Erlangen</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nordbeck, Dr</last_name>
    </contact>
    <investigator>
      <last_name>Nordbeck, Dr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>KMG Clinic Güstrow</name>
      <address>
        <city>Güstrow</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Westpfalz-Klinikum</name>
      <address>
        <city>Kaiserslautern</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Schumacher, Prof</last_name>
    </contact>
    <investigator>
      <last_name>Schumacher, Prof</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Clinic SH Campus Kiel</name>
      <address>
        <city>Kiel</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bonnemeier, Prof</last_name>
    </contact>
    <investigator>
      <last_name>Bonnemeier, Prof</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Clinic St. Georg</name>
      <address>
        <city>Leipzig</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Klein, Dr</last_name>
    </contact>
    <investigator>
      <last_name>Klein, Dr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>DHM</name>
      <address>
        <city>Munich</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kolb, Prof</last_name>
    </contact>
    <investigator>
      <last_name>Kolb, Prof</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Marien Hospital Papenburg Aschendorf</name>
      <address>
        <city>Papenburg</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yousef, Dr</last_name>
    </contact>
    <investigator>
      <last_name>Yousef, Dr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cardio Consil GmbH</name>
      <address>
        <city>Rostock</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Semmelweis Medical University</name>
      <address>
        <city>Budapest</city>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Merkely, Prof</last_name>
    </contact>
    <investigator>
      <last_name>Merkely, Prof</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Austria</country>
    <country>Czechia</country>
    <country>Germany</country>
    <country>Hungary</country>
  </location_countries>
  <verification_date>September 2020</verification_date>
  <study_first_submitted>January 11, 2019</study_first_submitted>
  <study_first_submitted_qc>February 11, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">February 15, 2019</study_first_posted>
  <last_update_submitted>October 8, 2020</last_update_submitted>
  <last_update_submitted_qc>October 8, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">October 9, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Heart Diseases</keyword>
  <keyword>CRT-D</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Failure</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

